Japan’s Ministry of Health, Labour and Welfare approved AstraZeneca’s Calquence for the treatment of treatment-naïve adult patients with chronic lymphocytic leukemia (CLL), including small lymphocytic lymphoma (SLL). The approval was supported by data from two trials, including a phase 3 study called ELEVATE-TN.